05/13/2026
I have been VERY out spoken about Librela from the very start. This drug is NOT approved from the FDA for humans and so what happened? Exactly this!
There is no long term studies from anywhere on the long term side affects of this drug on your pet.
I know we all want our pets to fell better but at what cost?
Librela (bedinvetmab) is an antibody injection for canine arthritis pain, but it can cause significant adverse effects. Reported side effects include serious neurological signs (seizures, ataxia/wobbliness, paresis), increased thirst/urination, urinary tract infections, and localized skin reactions, with some cases resulting in fatality or euthanasia, and now this is added to the list.
I had a vet offer this drug to one of our dogs and I had to say no 2 or 3 times to him. He continued to state that he had given it to hundreds of dogs already and he had given it to his own dog.
He was trying to make me feel like I was a bad pet parent for saying NO to something that wasn't researched properly.
If you want to take the time to research something that is being recommended to you or your pet, then do so! Do not let them pressure you into making a poor decision in the heat of the moment that could possibly have negative side affects long term.
The full link is in the post.
This brand new peer-reviewed clinical review highlights emerging safety concerns around anti nerve growth factor arthritis injections like Librela and Solensia. Based on post marketing reports and clinical observations, some dogs developed unusually rapid joint deterioration after treatment, including faster than normal arthritis progression, joint instability, and even structural collapse. In certain cases, these changes appeared after just one or two injections, while others developed more gradually over time. What makes these findings concerning is that they do not resemble typical arthritis, with veterinarians reporting abnormal bone formation, bone erosion, and widespread joint damage, sometimes affecting joints that were not previously identified as diseased. The review suggests a possible biological explanation, noting that nerve growth factor plays a role not only in pain signaling but also in maintaining joint health, meaning blocking it could interfere with the joint’s ability to adapt or repair. While these observations do not prove causation, they raise important questions and highlight the need for careful monitoring and further research.